Search
Alkermes Plc
ALKSAdd to Watchlist
44.990USD
+0.480+1.08%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
7.49BMarket Cap
48.39P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Alkermes Plc is 8.12, ranking 162 out of 389 in the Biotechnology & Medical Research industry. The average price target is 45.00, with a high of 58.00 and a low of 30.00.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
47.188
Target Price
+4.88%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Alkermes Plc
ALKS
17
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Alkermes Plc's expected revenue for the next quarter?
Alkermes Plc's expected revenue is 457.97M.
What is Alkermes Plc's price target?
Analysts forecast that Alkermes Plc's price target is USD 45.00, with the highest forecast at USD 58.00 and the lowest forecast at USD 30.00.
How have Alkermes PlcALKS's recent earnings per share performed?
The market expectation was USD -0.40, while Alkermes PlcALKS's earnings per share (EPS) for the previous quarter was USD 0.30. EPS for the next quarter is expected at USD -0.02.
What is the analyst rating for Alkermes Plc?
Based on the ratings of Alkermes Plc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
